INTRODUCTION
Carcinoma of the breast remains the most prevalent cancer diagnosed in women in the world. Although breast cancer mortality has declined in the last two decades, breast cancer continues to represent a major threat to the lives and productivity of women. The number of effective treatments for breast cancer is on the rise; however, the benefit from specific treatments to individual patients and the adverse events they experience vary considerably. Efficacy and safety of anticancer therapies may depend on tumor, treatment, and host characteristics.
Small variants in the germline DNA sequence (genotype) may lead to different expression of the encoded protein or to the expression of altered protein, and thus to a different health outcome (phenotype). 1, 2 The recent completion of the human genome project and advances in high throughput DNA sequencing and proteomic technologies may contribute to the understanding of interindividual variability in health outcomes. Most genetic variants occur in noncoding regions of the genome, and although such variants may result in functional consequences, most known variants that are associated with clinically important functional change are in the exons that code for protein expression. 3 While the clinical importance of a large number of pharmacogenetic variants is becoming more clear, the significance of the majority remains speculative while we await larger trials. This review is written in this context of a large amount of research that is rapidly maturing towards a point where testing in clinical populations will become common.
Pharmacogenetics may play a significant role in several aspects of breast cancer including prognosis at the time of diagnosis, response to specific treatments, and likelihood of adverse events to specific treatments. While a large amount of research has examined details of genetic predisposition to breast cancer, a relative paucity of work has been done to identify genetic variants that might predict a women's prognosis and response to treatment once breast cancer is diagnosed. Indeed, once breast cancer is diagnosed, a woman may be more interested in her chances of response to treatment than her risk of carrying a genetic variant that puts her at higher risk of developing the disease. 4 When primary breast cancer has developed, certain clinical characteristics of the tumor, such as lymph node metastases, tumor size, and grade, are used to predict prognosis. 5 Most clinicians offer treatment recommendations to an individual woman based on estimates of likelihood of recurrence with local treatment only (prognosis), co-morbidities, and possible treatment-related toxicities. Clinicians continue to struggle to identify sensitive tools that can help separate women who are not going to suffer a recurrence from women who are likely to suffer a recurrence. Pharmacogenomics is a technically robust technology that offers considerable potential to allow better identification of subgroups of patients that may be at sufficient risk of cancer recurrence to justify systemic treatment. Much recent research has focused on the genomics of the tumor itself and the possibility that gene expression within the tumor may be predictive of risk of relapse. 6, 7 Once a decision is made to administer systemic therapy, only a handful of genes or proteins are used to select specific treatments for breast cancer patients. Early results suggest that patterns of gene expression determined on primary tumors may predict sensitivity or resistance to common breast cancer treatments. 8, 9 Advances in genomics may also assist in predicting response to specific treatments. Genetic variants that might predict the composite results of treatment represented by tumor response and side effects may reside in the germline, since most tumor DNA remains the germline DNA of the patient. 10 Indeed, a woman's primary breast cancer is more likely to genetically resemble her metastatic foci than another woman's primary tumor with similar histological characteristics. 6 Pharmacogenomics of drug response may also be related to the genetic inheritance of single-nucleotide polymorphism (SNPs) or other changes such as insertions or deletions in important genes relevant to drug disposition and effect, including drug metabolizing enzymes, transporters, or drug targets.
Only a few predictors have been used to estimate an individual woman's risk of adverse events to specific agents or treatments. Older age, previous treatments, and co-morbid conditions may predict a higher chance of chemotherapy-related neutropenia. Germ line DNA characteristics may also play an important role in predict-ing who may be at a high risk of adverse events. For example, AfricanAmerican women may be at a higher risk of chemotherapy-related neutropenia resulting in treatment reductions and delays. 11 Genetically predictable side effects may correlate with the expression of individual susceptibility pathways in vulnerable tissues. The prospective knowledge of an individual's risk to develop adverse events could lead to a change in the proposed treatment or to intervention that may reduce the risk.
A central, but often unrecognized goal of pharmacogenetic research, is to use the revolution in genomics to allow the benefit of treatment and avoidance of toxicity to be made available to all patients, rather than only the subgroup that can tolerate currently used therapeutic regimens and respond well to them. Knowledge of the likelihood of response to treatment and the predictability of side effects may assist in individualizing treatment for women diagnosed with breast cancer.
PHARMACOGENETICS OF SYSTEMIC BREAST CANCER TREATMENTS
Systemic treatments for breast cancer are divided into hormonal interventions, chemotherapy, and novel agents. Antitumor activity or safety of specific agents may depend not only on drug dose and schedule but also on functional targets, drug metabolizing enzymes, and transporters. Some agents are prodrugs with one or more metabolites that may contribute to the drug's antitumor activity or to specific side effects. Prospective determination of genetic variants in drug metabolizing enzymes or drug transporters could be used to determine likelihood of response and/or propensity to adverse effects. Response to a specific agent may also depend on variants in the target of the treatment. It is possible that small genetic variations in the target may affect the response or toxicity related to the agent. In this review we will focus on the current knowledge of the role of pharmacogenetics in predicting efficacy and safety of standard and emerging breast cancer treatments.
HORMONAL THERAPY
More than 50% of primary breast cancers will express the estrogen receptor (ER) and/or progesterone receptor (PgR). Almost every woman with hormone receptor-positive disease will be offered some form of hormonal intervention to treat the cancer. Most women with early breast cancer will likely receive adjuvant tamoxifen for 5 years. Postmenopausal women may be offered aromatase inhibitors instead of or following tamoxifen, and premenopausal women may undergo ovarian suppression instead of or with tamoxifen. Tamoxifen has also been approved to reduce the incidence of a new breast cancer in women at high risk for the disease.
Tamoxifen
Among treatments for breast cancer, there is no better example of a targeted treatment than tamoxifen. Tamoxifen is a nonsteroidal parent drug with mixed agonist and antagonist activity. The drug exerts its effects by binding to the estrogen receptors and modulating estrogen-induced transcription. It is metabolized extensively through the cytochrome P450 system to its primary N-demethylated metabolite, but also to a number of potent antiestrogenic metabolites including 4-hydroxy-tamoxifen and 4-hydroxy-Ndesmethyl-tamoxifen (endoxifen, Figure 1) . 12 It is not known whether a specific metabolite or a relative ratio of several tamoxifen metabolites exerts its estrogenic effect in some tissues Figure 1 Tamoxifen metabolic pathway. The dominant metabolic route for tamoxifen is via N-demethylation to N-desmethyl tamoxifen. A relatively minor route is direct hydroxylation to 4-hydroxy-tamoxifen. The large amount of N-desmethyl tamoxifen present in plasma is reflected in the relatively large amount of endoxifen made from it, relative to lower concentration of 4-hydroxy-tamoxifen.
Pharmacogenetics in breast cancer treatment V Stearns et al such as bone and uterus or its antiestrogenic activity in the breast and/or central nervous system. Tamoxifen reduces the risk of breast cancer recurrence in hormone receptor-positive women by 50%. 13 While the presence of ER and/or PgR is critical for selection of patients who may benefit from tamoxifen, some hormone receptorpositive women will recur despite the treatment because of de novo or acquired resistance. Tamoxifen may rarely stimulate tumor growth. Primary resistance to tamoxifen has been linked to intratumoral characteristics such as cross-talk with HER2/neu (cerbB-2) or other growth factor receptors, imbalance of co-activators and co-repressors, or altered expression of other transcription factors that may modify the activity of the ER.
14 Pharmacogenetic factors such as polymorphisms in enzymes that metabolize tamoxifen or in its principal target (ie the ERa and ERb receptors) may also contribute to tamoxifen resistance. Several small investigations have demonstrated a possible link between mutations in the ER and tamoxifen resistance or tamoxifen-stimulated growth. 15, 16 For most women with hormone receptor-positive invasive breast cancer, the benefits of tamoxifen outweigh the possible risks. The decision may be more difficult for high-risk women considering tamoxifen to reduce the incidence of breast cancer. To date, four randomized clinical trials that included over 28 000 women have compared tamoxifen to placebo for breast cancer prevention. An overview of these studies suggests that tamoxifen reduces the risk of a new ERpositive breast cancer by 38% (95% confidence interval (CI) 28-46; Po0.0001). 17 Despite the large number of women enrolled in the studies of tamoxifen as a preventive agent, an improvement in mortality has not been demonstrated, and it is unlikely that such data will become available. In addition, tamoxifen has been associated with rare serious adverse effects, including uterine cancer and thromboembolic disease. Given the possible toxicity and the incomplete efficacy of the drug, tools that can help identify women who are most likely to benefit and/or least likely to suffer adverse events are needed.
Tamoxifen is metabolized in the liver by several cytochrome P450 enzymes. Polymorphisms in cytochrome P450 enzymes are prevalent in the general population. To date, over 40 individual alleles of CYP2D6 have been identified. A functional SNP in CYP2D6 or one of the other CYP enzymes may influence the relative concentration of each tamoxifen metabolite. As noted, it is not known whether tamoxifen is the most important antiestrogen or whether a single metabolite, relative concentrations of several metabolites, or some ratio of active species may contribute to the antitumor activity of the drug. It has been suggested that 4-hydroxy-tamoxifen, which is 100 times more potent than tamoxifen in terms of binding to the ER, may play a significant role in tamoxifen's antitumor activity. 18 Recent data suggest that other metabolites may be as important as 4-hydroxy-tamoxifen in tamoxifen's activity and may be influenced by pharmacogenetic effects. Women with a CYP2D6 polymorphism had significantly lower concentrations of the antiestrogenic metabolite 4-hydroxy-N-desmetyl-tamoxifen (endoxifen) compared to women who carry a wild-type genotype. 12 Endoxifen was as potent an antagonist of estrogen activity as 4-hydroxy-tamoxifen in estrogen-deprived MCF-7 cells. Studies conducted in human liver microsomes confirmed that metabolism from tamoxifen to endoxifen occurs primarily via the genetically polymorphic CYP2D6 from N-desmethyl-tamoxifen ( Figure 1 ). 19 In a larger prospective trial of women prescribed tamoxifen and who were tested for CYP2D6, those who carry functionally variant alleles had significantly lower concentrations of endoxifen, but not of tamoxifen, N-desmethyl-tamoxifen, or 4-hydroxy-tamoxifen. 20 An understanding of the clinical importance of this finding awaits further trials.
In another study, investigators evaluated the prevalence of polymorphism in human sulfotransferase 1A1 (SUL-T1A1) and risk of death of 160 women who received adjuvant tamoxifen and 177 who did not. SULT1A1 catalyses sulfation of estrogenic compounds and is responsible in part for elimination of 4-hydroxy-tamoxifen. A polymorphism in exon 7, designated SULT1A1*2, is associated with a twofold lower enzyme activity compared to the more common SULT1A1*1 allele. In the tamoxifen-treated women, the hazard ratio (HR) of any death was higher in SULT1A1*2 homozygous carriers (HR 2.9, 95% CI: 1.1-7.6). 21 Women who did not receive tamoxifen had similar outcomes regardless of SULT1A1 status. This preliminary study has several limitations, such as inclusion of a very heterogeneous group of women, and the results were opposite to the authors' hypothesis that reduced elimination of 4-hydroxy-tamoxifen might be associated with a better outcome. However, these results suggest that the differential outcome in tamoxifen-treated women may be related to the presence of a genetic polymorphism.
Ongoing prospective studies are evaluating the relative ratio of tamoxifen and its metabolites and the drug's activity in different systems such as bone and liver in women with wild type or polymorphic CYP2D6. The risk of tamoxifen-associated uterine cancer increases with age. Whether mutations in drug metabolizing enzymes or other genes may contribute to the toxicity is not known. 22 Tamoxifen is also associated with an increased risk of thromboembolic disease, but the effect of tamoxifen on cardiovascular events in women with coronary artery disease remains unclear. The largest breast cancer prevention trial (BCPT) conducted by the National Surgical Adjuvant Bowel and Breast Project (NSABP, P-1 trial) included 1048 women with documented coronary artery disease who were randomized to tamoxifen or placebo. The number of cardiac events was not significantly different (19 events in the placebo group and 25 in the tamoxifen group). 23 The effect of genotype on the ability of estradiol and tamoxifen to induce platelet aggregation could possibly explain the effects of these drugs on cardiovascular parameters. For example, women who Pharmacogenetics in breast cancer treatment V Stearns et al carry a homozygous variant genotype in exon 7 of endothelial nitric oxide synthase (eNOS) may be more vulnerable to platelet aggregation by estrogens than others. 24 In women enrolled in the International Breast Cancer Intervention Study (IBIS-1) of tamoxifen, no difference in prothrombin and factor V Leiden mutations was seen in women who developed venous thromboembolism vs not. 25 Genetic polymorphisms in ER may also influence tamoxifen-related toxicity or other benefits associated with the drug. We have reported that 4-months of tamoxifen treatment was associated with reduction in plasma lipid concentrations in women with wild-type ER but not in those with ER germline variants. 26 In other studies, tamoxifen treatment was associated with a significantly higher increase in bone mineral density in women who carried a 21 CA repeats allele in intron 5 of ERb compared to noncarriers. 27 The results of small investigations conducted to date suggest that genetic variability in the metabolism of tamoxifen may have important clinical implications. Ongoing investigations may clarify whether changes in tamoxifen metabolism will translate to a differential outcome. Pharmacogenetics may provide the needed tools to separate the women who are most likely to benefit from tamoxifen treatment, from those who are less likely to benefit from the drug, or even be harmed, emphasizing the need to collect germline DNA as part of prospective clinical trials.
Aromatase Inhibitors
Aromatase inhibitors block the conversion of androgens to estrogens, exerting antitumor activity by depletion of circulating estrogens. Several studies have demonstrated superiority of aromatase inhibitors over tamoxifen as first-line treatment for metastatic breast cancer. 28 In the large adjuvant trial designated ATAC (Arimidex, Tamoxifen, Alone or in Combination), anastrozole was associated with significantly fewer breast cancer recurrences compared to tamoxifen or the combination of anastrozole with tamoxifen. 29 The results of this study led to an approval of anastrozole for early stage breast cancer by the Food and Drug Administration (FDA), allowing for more than one adjuvant hormone therapy option for postmenopausal women. The use of 5 years of letrozole following 5 years of tamoxifen further improves disease-free survival. 30 Thus, the use of aromatase inhibitors is likely to increase. However as with tamoxifen, not all hormone receptor-positive women will benefit from aromatase inhibitors. Adverse effects of aromatase inhibitors, which result from reduction in circulating estrogens, may include bone loss, arthralgias/mylagias, and hot flashes.
In the adjuvant setting, the presence of hormone receptors and predisposition to drug-specific adverse events are used to select tamoxifen or aromatase inhibitor treatment for individual women. Pharmacogenetic effects on the activity or safety of aromatase inhibitors have not been described. Pharmacogenetic tools that may help predict which patients are most likely to benefit or suffer toxicity from aromatase inhibitors might include tests for variants in aromatase (CYP19). The presence of an SNP in exon 10 of aromatase (Arg264Cys) is associated with differential RNA levels and a possible increased risk of developing breast cancer and prostate cancer. 31, 32 However, a correlation between the variant and response to breast cancer treatments has not been investigated. Other polymorphisms in aromatase include a number of TTTA repeats in intron 4. A rare polymorphic allele of CYP19 (repeat (TTTA)12) has been reported to be significantly more frequent in breast cancer patients than in controls, 33 but a correlation between this polymorphism and response to treatment has not been examined. Interestingly, a greater number of repeats has been associated with bone gain in women who receive estrogen, 34, 35 suggesting that polymorphic variants of aromatase may influence bone health of women treated with inhibitors. Variants in CYP19 may also influence breast density. 36 Whether reduction in breast density on tamoxifen or aromatase inhibitor treatment will directly correlate with reduced risk of developing a new cancer or a recurrence is not known. Finally, polymorphism in enzymes that metabolize aromatase inhibitors may also be associated with resistance. CYP1A2, CYP2C9, and CYP3A have been associated with anastrozole metabolism. 37 Ongoing studies will evaluate polymorphisms of aromatase and enzymes that metabolize aromatase inhibitors with estrogen concentrations, breast density, and bone density.
CHEMOTHERAPY
Several single agent and combination chemotherapy regimens are effective treatments for breast cancer. In metastatic disease the goal of therapy is to improve time to progression, quality of life and possibly overall survival. Cure is an attractive goal but is rarely achieved in this setting. In contrast, in the adjuvant setting, the ultimate goal is to improve overall and/or diseasefree survival. The optimal dose and schedule of chemotherapy are generally determined in phase I clinical trials, usually in the metastatic setting, when dose-limiting toxicities are assessed and a maximum tolerated dose is determined. Then, the dose and schedule may be further refined in phase II and III trials. Promising drugs are then tested in the adjuvant setting. Most chemotherapy drugs are administered to an individual based on a body surface area (BSA) calculated from the patient's height and weight or, less often, area under the curve (AUC). Currently, there is no consensus regarding how to dose people who are not at their ideal body weight, whether adjustments should be made based on age and toxicity, or lack of it, to the treatment, or whether BSA should be used to determine dose of chemotherapy and novel treatments. 38 Many women and their healthcare professionals will accept modest drugrelated toxicity for modest improvement in outcome. However, decisionmaking is especially difficult for women with very small tumors that are likely cured of their cancer by local modalities who may gain little benefit, Pharmacogenetics in breast cancer treatment V Stearns et al if any, from the addition of adjuvant chemotherapy. If we were able to quantify the benefit an individual woman may derive from a specific treatment and her risk of developing serious, life-threatening, or long term toxicities, she could then weigh the specific benefits and possible adverse events to make a decision regarding treatment. This key information could make a risk and benefit discussion more personal and less theoretical.
In adjuvant breast cancer, combination chemotherapy has been the standard of care for many women for decades. Combinations of cyclophosphamide and/or anthracycline-based therapy are usually administered. Some common agents administered in breast cancer are summarized in Table 1 . In metastatic disease, singleagent therapies are often administered although several combinations have also been used. Several tumor characteristics, such as poor grade and lack of hormone receptors, have been associated with improved response to chemotherapy; however, specific predictors of response to individual chemotherapy agents are not yet identified. Likewise, pharmacogenetic factors have been suggested but not proven to predict toxicity to treatment.
Inherited variation in the activity of drug-metabolizing enzymes that handle some chemotherapeutic agents is well recognized. This variation may result in interindividual differences in pharmacokinetics of specific agents and may be associated with treatment-related toxicity. For example, it is well established that people with the rare recessive deficiency of dihydropyrimidine dehydrogenenase enzyme (DPD), which reduces 5-fluorouracil to an inactive metabolite, dehydrofluorouracil, will have delayed clearance of the drug and therefore greatly prolonged half-life in the plasma. Due to the long exposure to the parent drug, people with DPD deficiency will suffer increased toxicity, especially neurotoxicity. Knowledge of pharmacogenetic variables that may influence response or risk for adverse events is important both in the metastatic and adjuvant treatment of breast cancer. If we could select the treatment that is most likely to provide benefit We will briefly review chemotherapy agents that are commonly used in breast cancer as well as potential pharmacogenetic factors that may affect their use (Table 2) . Only a few small retrospective analyses have been conducted and germline DNA samples have rarely been collected in prospective trials to examine pharmacogenetic effects on response or toxicities to chemotherapy in breast cancer.
Cyclophosphamide (Cytoxan)
Specific drugs used in breast cancer chemotherapy regimes have evolved over the years, but cyclophosphamide has remained a stable component in many of the combinations. Cyclophosphamide (Cytoxan) is rarely used as a single agent in breast cancer and thus it is difficult to ascertain whether the efficacy or toxicity seen in combination treatments is related to cyclophosphamide or other agents in the combination. Cyclophosphamide is also an integral component of several high-dose chemotherapy combina- Cyclophosphamide is a mechlorethamine-analog, with activity against many tumors. It is a pro-drug that requires metabolic activation by cytochrome P450 enzymes to 4-hydroxycyclophosphamide before it exerts its effects. 39 4-Hydroxy-cyclophosphamide equilibrates with aldophosphamide, and the latter can undergo chemical decomposition into phosphoramide mustard and acrolein. Phosphoramide mustard is an active DNA alkylating metabolite. Acrolein is a toxic byproduct, which has been implicated as the cause of hemorrhagic cystitis, illustrating the significance of drug metabolism and consequential adverse effects. Aldophosphamide can also be metabolized into the inactive metabolites carboxyphosphamide and 4-ketocyclophosphamide.
Multiple cytochrome P450 enzymes have been implicated in the metabolic activation of cyclophosphamide, including CYP2A6, CYP2B6, CYP2C19, CYP2C9, CYP3A4, and CYP3A5, [40] [41] [42] [43] but the relative importance of each of these enzymes in the treatment of breast cancer with cyclophosphamide remains unknown. Of these, CYP2B6, CYP2C19, CYP2C9, and CYP3A5 have known variant alleles that influence their expressed proteins, and may be associated with altered metabolic activity and result in the wide interpatient variability that is seen in cyclophosphamide-treated individuals. 44, 45 It is possible that genetic differences in cytochrome P450 enzymes may increase the likelihood of myelosuppression and/or other cyclophosphamide related toxicities. If we could screen for genetic predisposition to drug-related toxicity, we could offer vulnerable women prophylactic treatments, such as the use of colony stimulating growth factors to prevent myelosuppresion.
Glutathione-S-transferase (GST) detoxifies mutagenic and cytotoxic DNA-reactive metabolites. GST may be duplicated, deleted, or mutated, and these genetic changes may alter the function of the enzyme. Deleted or mutated GST may be associated with less detoxification of cyclophosphamide, resulting in more available drug compared to the wild-type enzyme. In a retrospective analysis of women who received adjuvant cyclophosphamidebased regimens, polymorphic GST (Ile105Val) was indeed associated with improved overall survival compared to women with wild-type enzyme. 46 Genetic predisposition may also be an important predictor for long term and potentially serious toxicities of chemotherapies. Cyclophosphamide and other alkylating agents have been implicated in the risk for secondary leukemia, especially when administered in high dose. Although direct correlation between genetic variability and risk of cyclophosphamide-associated leukemia is not available, investigations in other cancers suggest that treatment-related leukemias are most often seen in patients with rare cancer predisposition syndromes or in those with polymorphisms in drug metabolizing enzymes that may result in impaired detoxification of the agents or inefficient repair of agentinduced damage. 47, 48 Identification of possible candidates may be important to gauge risk for such devastating long-term effects. This is especially important for women who may have only a small benefit from the chemotherapy.
METHOTREXATE
While single-agent methotrexate is not a common approach for the treatment of breast cancer, one of the oldest and most widely used regimens is CMF (cyclophosphamide, methotrexate, 5-fluorouracil). Methotrexate inhibits dihydrofolate reductase, resulting in partial depletion of reduced folates. The regimen is fairly well tolerated by most women, but a small portion may suffer acute myelosupression. Investigators have hypothesized that polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene may result in differential toxicity to CMF. MTHFR regulates the pool of intracellular folates that are available for nucleic acid and protein synthesis by converting 5,10-methylenetetrahydrofolate to 5-methylenetetrahydrofolate, which is a methyl donor in the conversion of homocysteine to methionine during protein synthesis. An SNP in exon 4 of the MTHFR gene (C677T) may result in protein with a lower activity, 49 altering the distribution of intracellular folates and leading to retention in folates. Breast cancer patients with the TT genotype may be more sensitive to bone marrow toxicity during CMF treatment. In a small retrospective analysis, TT genotype was detected in five of six patients who suffered severe toxicity to the first cycle of CMF, compared to a 20% prevalence in women who did not suffer unusual toxicity. 50 
Anthracyclines
The anthracycline antibiotic doxorubicin (Adriamycin) is one of the most commonly used chemotherapy agents in breast cancer. Doxorubicin forms a complex with DNA by intercalation between base pairs, leading to formation of free radicals and subsequent inhibition of DNA topoisomerase II catalytic activity. In addition, the drug activates protein kinase C-mediated signal transduction pathways. Doxorubicin is metabolized in the liver via cytoplasmic aldoketoreductases to an active metabolite, doxorubicinol and via CYP450 enzymes to inactive doxorubicinol and 7-deoxydoxorubicinone metabolites. Doxorubicin is also a substrate of P-glycoprotein, the product of the MDR-1 gene. 51 Several candidate gene polymorphisms may be important in doxorubicin efficacy or toxicity. In vitro, GST and the MDR-1 may contribute to doxorubicin resistance. 52 As noted, GST catalyzes reduction of products that result from reactive oxidant damage to DNA and lipids, such as metabolites of the chemotherapy agents, cyclophosphamide and doxorubicin. In a retrospective analysis of 251 women who received combination CAF (cyclophosphamide, doxorubicin, 5-fluorouracil), those homozygous for the deletions GSTM1*0 and GSTT1*0 were less likely to suffer disease recurrence and/or death compared to those with wild-type enzyme. 53 Genetic variants that influence the activity of this multidrug transporter have been shown to influence the disposition of Pharmacogenetics in breast cancer treatment V Stearns et al a number of drugs. 51 Whether the doxorubicin metabolism pathway or individual metabolites may be responsible for the toxicity associated with the drug is not known. In a study of 68 women who received preoperative anthracycline with or without taxanes, response rates were greater for those with wild-type MDR-1 compared to the TT genotype in exon 26. 54 Epirubicin is the 4 0 isomer of doxorubicin, and its clearance correlates significantly with hepatic function. Epirubicin may be less cardiotoxic than doxorubicin perhaps because it is handled differently by the liver, via a glucuronidation route that is available to epubicin and epirubicinol. Indeed the formation of epirubicin glucuronide by liver UDP-glucuronosyltransferase (UGT) is its main inactivating pathway. The glucuronide metabolites of epirubicin and epirubicinol are not active, but could divert epirubicin from free radical formation, which may induce cardiotoxic effects. This may explain, at least in part, a lower cardiotoxicity of this new anthracycline relative to that of the progenitor. Ratain et al have determined that the specific glucuronidating enzyme of epirubicin is UGT2B7, 55 a genetically polymorphic enzyme. However, genetic variants that influence epirubicin metabolism in vivo have not been described.
Taxanes
Paclitaxel (Taxol) is a novel chemotherapy agent derived from the bark of the yew tree (Taxus Brevifolia) that promotes microtubule assembly and stabilizes tubulin formation. Docetaxel (Taxotere) is a semisynthetic analog of paclitaxel. The taxanes inhibit proliferation by inducing mitotic block; however, the drugs may have other properties including antiangiogenic effects that have not been entirely elucidated.
Paclitaxel is metabolized by CYP3A4 to a minor active metabolite and by CYP2C8 to a major inactive metabolite 6-8-hydroxpaclitaxel. Paclitaxel is also a P-glycoprotein substrate. Several CYP2C8 polymorphisms have been identified including CYP2C8*3, CYP2C8*4, and CYP2C8*2. In vitro, CYP2C8*3 and, to a lesser extent, CYP2C8*4 were associated with diminished catalytic activity of the conversion of the parent drug to 6-ahydroxytaxol compared to the wildtype genotype.
56 CYP2C8*2 is associated with a lower clearance of paclitaxel compared to the wild-type allele. 57 Whether this change in metabolism may translate to an alteration in paclitaxel's efficacy and/or toxicity is not known. Pharmacodynamic pharmacogenetics may also play a role in paclitaxel efficacy, but in a study of 82 women with breast cancer who were treated with paclitaxel, mutations of class I b-tubulin were detected within 18% of the tumors and were not associated with a differential response to the drug. 58 The clearance of docetaxel is decreased with older age, decreased BSA, increased levels of albumin, and elevated bilirubin or transaminases. 59 Docetaxel undergoes hydroxylation by CYP3A4 and CYP3A5. Like paclitaxel, docetaxel is a substrate of Pglycoprotein. A great interindividual variability in the activity of CYP3A has been observed in humans. 60 In vitro, CYP3A activity in hepatic tissues is also variable. 61 Investigators have hypothesized that it is possible to assess the activity of CYP3A4 by analyzing metabolism of erythromycin and then optimize the dose of docetaxel that can then be determined for an individual. 62 In a study of 21 patients with heavily pretreated sarcoma with good hepatic function who received docetaxel 100 mg/m 2 , low erythromycin breath test results correlated directly with reduced docetaxel clearance. 61 The patients with the worse toxicities were indeed the patients with the lowest erythromycin breath test results and docetaxel clearance. The same investigators have subsequently used baseline erythromycin breath test results to determine the optimal dose of docetaxel for women with breast cancer. In a preliminary manner, the lowest docetaxel dose administered (which by definition correlates with lowest erythromycin breath test results) was associated with the highest AUC of the drug while the patients who received the highest dose of the drug had the lowest AUC. 63 Whether this noveldosing algorithm will translate to an improved efficacy or toxicity for individual patients is not known.
The importance of CYP3A5 in docetaxel metabolism has not been defined. Common polymorphisms in CYP3A5 may result in altered hepatic clearance of several drugs such as the commonly prescribed erythromycin. Thus, it is possible that an individual with a polymorphic CYP3A5 may require less than the standard prescribed dose of the drug compared to an individual with a wild-type enzyme. 64 Only 30% of Caucasians express the enzyme; however, CYP3A5 expression, and thus perhaps its significance, is higher in African Americans. 65 An SNP in the third intron of CYP3A5 occurs commonly and results in a truncated nonfunctional enzyme. The CYP3A5*3 (A22893G) allele has been correlated with alternative splicing and a truncated protein and is the most common reason for loss of expression of the enzyme in hepatic tissue. The CYP3A5*6 polymorphism (A30597G) results in deletion of exon 7 and a low CYP3A activity. Docetaxel metabolism may correlate with an aggregate expression of CYP3A enzymes. 66 5-Fluorouracil and Capecitabine 5-Fluorouracil has been used in the treatment of many solid tumors for several decades. The newer oral formulation, capecitabine (Xeloda), is also widely used. 5-Fluorouracil is reduced to the inactive metabolite dehydro-fluorouracil via DPD enzyme. DPD activity may be deficient in 3-5% of individuals, but a complete deficiency is extremely rare. 67 Tumors with low expression of DPD mRNA and activity are associated with improved response to fluorouracil and improved survival. 68 Over 20 functional mutations have been reported in the DPD gene, and it is possible that more than one gene mutation is required to predict for the lack of function of the enzyme and risk of severe toxicity and death. Thus, the clinical utility of genetic testing for specific mutations is unknown. 69 Pharmacogenetics in breast cancer treatment
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Despite the known pharmacogenetic correlate between DPD deficiency and toxicity, clinicians have rarely determined this pharmacogenetic predisposition prior to treatment recommendations.
Thymidylate synthase (TS), the target of fluorouracil, and a folate-dependent enzyme, play an important role in cellular expression of several genes and can affect cell proliferation and death. 70 Thus, a change in the expression or function of the gene may result in altered chemosensitivity. Specifically, TS catalyzes deoxyuridylate (dUMP) to thymidilate (dTMP). dTMP is then metabolized to dTTP and incorporated in DNA synthesis. The TS gene has been shown to have different numbers of tandem repeat sequences (2, 3, 4, and 9 respectively in TSER*2, TSER*3, TSER*4, and TSER*9) that cause a differential activity by causing increased expression which is correlated with worse response. [71] [72] [73] A polymorphism in the tandem repeat sequence of the TS gene is associated with improved response and survival of colorectal cancer patients. 74 Prospective investigations of this type in patients with breast cancer receiving capecitabine are ongoing.
Other Chemotherapies
Other treatments that may be used alone or in combination with other chemotherapies for breast cancer include vinorelbine, gemcitabine, liposomal anthracyclines, cisplatin, and carboplatin. These agents are usually prescribed as third-line therapies in metastatic breast cancer, when women likely have chemoresistant disease and poor performance status. Thus, possible pharmacogenetic effects of these agents on efficacy and toxicity may be difficult to ascertain.
NOVEL AGENTS
Many novel therapies that target a specific protein or process are under preclinical and/or clinical investigation. Specific treatments may target processes such as signal transduction, antiangiogenesis, invasion, and metastases. Trastuzumab represents an example of an effective targeted therapy that is efficacious as a single agent or in combination with chemotherapy in women whose tumors overexpress or amplify c-erbB-2 or HER-2/neu. Resistance to trastuzumab may be associated with more specific tumor characteristics such as the need for an activated HER2 or proliferation of non-HER2 expressing cells. Polymorphisms in the HER2 receptor have been evaluated in context of breast cancer risk. Pharmacogenetic effects of the target or enzymes that may metabolize trastuzumab and may predict response or toxicity to the treatment have not been studied.
SUMMARY
Preliminary pharmacogenetic data strongly suggest an important role for the use of germline genetic information in the individualization of treatment and prevention of breast cancer. The potential value of these data as individual genotypic predictors may be valuable or, more likely, patterns of genetic markers analogous to the expression profiles obtained from tumor tissue may allow more powerful prediction of who will respond best to a specific treatment or regimen. For the potential of genomic research to be fulfilled, prospective trials with clinical outcomes as end points will have to include the collection of germline DNA either in blood, or by buccal swab. Although the collection of DNA for such pharmacogenetic testing raises a number of important ethical issues that mandate the use of an appropriate informed consent process, sufficient experience has now been catalogued to allow broad guidelines for such an informed consent to be constructed. Investigators are now equipped with robust genetic tools with which to examine in detail multiple relationships between germline genetic variants and response to the treatment of breast cancer. A future in which genetics will contribute to the precise prescription of treatments for breast cancer, with the attendant benefits to patients, is now foreseeable, but much research remains to be done. Critical to this work will be the prospective collection of germline DNA from patients enrolled in large clinical trials of defined treatment with clinical determination of outcome.
